Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Key Inclusion Criteria:

• Healthy male or female participants between 18 and 65 years of age (inclusive) at the time of Screening (Japanese participants must be first-generation Japanese)
• In good health, determined by no clinically significant findings from medical history, physical examination, ECG, vital signs measurements, and clinical laboratory evaluations
• Body mass index between 18 and 30 kg/m^2 at the time of Screening
• Females of nonchildbearing potential

Key Exclusion Criteria:

• History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease
• History or current signs or symptoms of cardiovascular disease
• History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in
• History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
• Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus test at Screening
• History of alcoholism or drug/chemical abuse within 1 year prior to Check-in
• Use of tobacco- or nicotine-containing products within 6 months prior to Check-in
• Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Screening or Check-in
• Female participants with a positive pregnancy test at Screening or Check-in
• Female participants lactating/breastfeeding or who plans to breastfeed during the study through 90 days after the end of study (EOS) visit
• Donation of blood from 3 months prior to Check-in, plasma from 2 weeks prior to Check-in, or platelets from 6 weeks prior to Check-in
• Unwilling to abide with study restrictions